GLP-1

The evidence provided offers limited research specifically focused on GLP-1 compounds, with most studies examining related medications or broader metabolic conditions.

Key Clinical Trials

The most relevant study was a completed Phase 3 trial (NCT00518882) that directly compared GLP-1 receptor agonists, examining the effects of adding either liraglutide or exenatide to existing treatments for blood glucose control in patients with type 2 diabetes. However, the sample size and detailed results are not provided in the available evidence.

Several completed observational studies explored related metabolic pathways, including investigations of glucagon resistance in patients with non-alcoholic fatty liver disease (NAFLD) and the metabolic effects of glucagon during oral glucose challenges, though these did not directly study GLP-1 compounds.

Recent Research Papers

Recent publications from 2026 have examined drugs in the broader incretin class. A pharmacovigilance study analyzed the safety profile of tirzepatide (a dual GIP/GLP-1 receptor agonist) using real-world data from the FDA Adverse Event Reporting System database, though specific safety findings are not detailed in the available evidence.

Another 2026 study investigated bofanglutide, described as a "novel oral" compound, examining its safety, tolerability, and pharmacokinetics in healthy Chinese participants through single and multiple-dose testing. The study design appears to be a Phase 1-type evaluation, but sample sizes and specific outcomes are not provided.

A comparative effectiveness study published in 2026 used target trial emulation methodology to compare GLP-1 receptor agonist plus SGLT2 inhibitor combination therapy versus monotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes.

Evidence Limitations

The available evidence provides only limited details about study methodologies, sample sizes, and specific outcomes for GLP-1-related research. Most abstracts lack the detailed results needed for comprehensive clinical interpretation. Additionally, several studies focus on related but distinct compounds or broader metabolic conditions rather than direct GLP-1 research.

This synthesis is based solely on the limited evidence provided and should not be used for clinical decision-making. Consult current medical literature and healthcare professionals for comprehensive treatment guidance.